Capricor Therapeutics Faces Class Action Lawsuit After Stocks Plummet by 64%

Capricor Therapeutics Faces Legal Action Amid Major Stock Plummet

In a significant turn of events, Capricor Therapeutics, Inc. finds itself embroiled in a class action lawsuit following a staggering 64% drop in its stock price. This drastic decline is reportedly tied to allegations of securities fraud related to the company’s clinical data and misstatements regarding their lead product candidate, Deramiocel.

Details of the Lawsuit

The law firm Bleichmar Fonti & Auld LLP has stepped forward to represent the investors in this case. The class action lawsuit was officially filed against Capricor, certain senior executives, and alleges that there were serious violations of federal securities laws, which contributed to the steep decline in stock value. Investors who acquired Capricor’s securities have been urged to seek information and potentially join the lawsuit, with a deadline of September 28, 2026, for appointing a lead plaintiff.

The court overseeing this case is the U.S. District Court for the Southern District of California. The nature of the allegations centers on a lack of transparency from Capricor regarding the clinical data supporting Deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy.

Why Did Capricor’s Stock Plummet?

Capricor is a biotechnology company that, until recently, was focused on developing cell-based therapies for rare diseases. Its flagship product candidate, Deramiocel, was anticipated to make a significant impact in treatment options for Duchenne muscular dystrophy. However, following a Complete Response Letter issued by the FDA in July 2025, which indicated that Capricor's application lacked sufficient evidence of effectiveness, investor confidence took a hit.

Amidst these events, the lawsuit claims that Capricor failed to disclose critical changes in the statistical analysis plan that were made for evaluating the efficacy of Deramiocel, stating that the FDA had not approved these modifications before the Biologics License Application (BLA) resubmission.

On July 27, 2026, the FDA posted briefing documents prior to an advisory committee meeting that pointed out potential issues with Capricor's methodology for analyzing clinical data, which ultimately fueled investor fears leading to a stock drop of $12.70 per share, plummeting from $19.70 to $7.00 in just overnight trading.

Moreover, during the FDA advisory committee meeting held on July 29, 2026, the panel reported that the evidence did not support Deramiocel's efficacy for treating DMD-related cardiomyopathy based on a non-binding vote. This further impacted the stock price, which fell another 36% on July 30, 2026.

What Should Investors Do?

Investors who believe they have suffered losses from their investment in Capricor Therapeutics are encouraged to take action. The firm Bleichmar Fonti & Auld LLP has stated that representation will be based on a contingency fee arrangement, meaning that clients will not incur costs unless the case is successful. This provides investors an opportunity to recover losses without upfront financial risk.

For those interested in joining the class action or seeking more information, it’s advised to visit BFA Law's dedicated webpage regarding the case.

Conclusion

The situation with Capricor Therapeutics serves as a stark reminder of the volatility and risks associated with investing in biotech firms, particularly those dealing with groundbreaking therapies yet to receive full regulatory approval. As the lawsuit unfolds, all eyes will be on the courtroom proceedings and the potential consequences for both the company and its shareholders. Investors are advised to stay informed and consider their options carefully.

For additional details, please visit BFA Law - Capricor Class Action Lawsuit.